{"id":"nbp606","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, NBP606 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin.","oneSentence":"NBP606 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:44.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02201030","phase":"PHASE3","title":"Immunogenicity and Safety Study of NBP606 in Healthy Infants","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-09-06","conditions":"Pneumococcal Infections","enrollment":577},{"nctId":"NCT02927444","phase":"PHASE3","title":"Immunogenicity and Safety Study of NBP606 in Healthy Toddlers","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2015-11-04","conditions":"Pneumococcal Infections","enrollment":462},{"nctId":"NCT02079207","phase":"PHASE3","title":"Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2013-12","conditions":"Pneumococcal Infections","enrollment":767}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NBP606","genericName":"NBP606","companyName":"SK Chemicals Co., Ltd.","companyId":"sk-chemicals-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"NBP606 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}